Pfizer is discontinuing a phase 3 study of sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for the first-line treatment of patients with advanced breast cancer.
Pfizer is discontinuing a phase 3 study of sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for the first-line treatment of patients with advanced breast cancer. An independent data monitoring committee stated that treatment with sunitinib plus paclitaxel would not meet the primary end point of superior progression-free survival versus bevacizumab plus paclitaxel.
Other trials of sunitinib have not been affected, including a phase 3 trial evaluating sunitinib plus docetaxel versus docetaxel alone for the first-line treatment of advanced breast cancer and a phase 3 trial evaluating sunitinib plus capecitabine versus capecitabine alone for the second-line treatment of advanced breast cancer.
Pfizer announced in April that it was discontinuing a phase 3 study of sunitinib as monotherapy for the treatment of advanced breast cancer (see Sunitinib trial for advanced breast cancer discontinued).
Employers Face Barriers With Adopting Biosimilars
March 1st 2022Despite the promise of savings billions of dollars in the United States, adoption of biosimilars has been slow. A roundtable discussion among employers highlighted some of the barriers, including formulary design and drug pricing and rebates.